Table 6 Number of patients with BDG (cutoff 80, 100 and 200 pg/mL) CAGTA, MANNAN biomarkers and Candida PCR positives used combined in the five study groups

BDG ≥80 pg/mL

CAGTA

21 (43.8)^a

75 (57.7)^a

21 (87.5)^b

18 (90.0)^b

10 (90.9)^b

< .001

Mannan-Ag

21 (43.8)^a

71 (54.6)^a,c

21 (87.5)^b

16 (80.0)^b

9 (81.8)^b,c

<.001

Mannan-Ab

21 (43.8)^a

61 (46.9)^a

19 (79.2)^b,c

15 (75.0)^c

8 (72.7)^a,c

.002

C-PCR

14/23 (60.9)

32/54 (59.3)

5/8 (62.5)

11/14 (78.6)

8/11 (72.7)

.724

BDG ≥100 pg/mL

CAGTA

21 (43.8)^a

72 (55.4)^a

20 (83.3)^b

16 (80.0)^b

10 (90.9)^b

< .001

Mannan-Ag

21 (43.8)^a

68 (52.3)^{a, c}

19 (79.2)^b

14 (70.0)^{a, b, c}

9 (81.8)^c

.009

Mannan-Ab

21 (43.8)

57 (43.8)

16 (66.7)

13 (65.0)

8 (72.7)

.053

C-PCR

14/23 (60.9)

28/54 (51.9)

5/8 (62.5)

10/14 (71.4)

8/11 (72.7)

.606

BDG ≥200 pg/mL

CAGTA

16 (33.3)^a

54 (41.5)^a

19 (79.2)^b

14 (70.0)^b

10 (90.9)^b

< .001

Mannan-Ag

15 (31.2)^a

52 (40.0)^a

18 (75.0)^b

13 (65.0)^b

9 (81.8)^b

< .001

Mannan-Ab

13 (27.1)^a

33 (25.4)^a

13 (54.2)^b

12 (60.0)^b

8 (72.7)^b

< .001

C-PCR

10/23 (43.5)

21/54 (38.9)

3/8 (37.5)

10/14 (71.4)

8/11 (72.7)

.089

CAGTA positive

Mannan-Ag

15 (31.2)^a

63 (48.5)^b

21 (87.5)^c

11 (55.0)^a,b

10 (90.9)^c

< .001

Mannan-Ab

14 (29.2)^a

53 (40.8)^a,c

18 (75.0)^b

12 (60.0)^b,c

8 (72.7)^b

< .001

C-PCR

8/23 (34.8)

25/54 (46.3)

5/8 (62.5)

6/14 (42.9)

8/11 (72.7)

.278

C-PCR positive

Mannan-Ag

5/23 (21.7)^a

21/54 (38.9)^a

5/8 (62.5)^a,b

7/14 (50.0)^a

8/11 (72.7)^b

.037

Mannan-Ab

8/23 (34.8)

19/54 (35.2)

1/8 (12.5)

7/14 (50.0)

8/11 (72.7)

.073

Mannan-Ag positive

Mannan-Ab

13 (27.1)^a

51 (39.2)^a,b

17 (70.8)^c

12 (60.0)^b,c

5 (45.5)^a,c

.003